Introduction {#section5-1753465816667121}
============

Lung cancer is usually diagnosed in older adults. In the USA, more than 50% of lung cancer cases are diagnosed in patients who are over 65 years of age, with a peak incidence between 65 years and 74 years \[[@bibr6-1753465816667121]\]. Currently, lobectomy combined with mediastinal lymph node sampling or dissection is the preferred treatment for patients with stage I non-small cell lung cancer (NSCLC) \[[@bibr16-1753465816667121]\]. However, many patients are not candidates for complete lobectomy because of severely compromised pulmonary function, advanced age, or other comorbidities. For these patients, the surgical technique of limited resection is frequently used \[[@bibr21-1753465816667121]\]. Moreover, results from several previously published studies suggest that limited resection may provide an adequate alternative for patients with stage I NSCLC with a tumor size of 2 cm or less (T1a), especially for elderly patients \[[@bibr13-1753465816667121], [@bibr11-1753465816667121]; [@bibr8-1753465816667121]; [@bibr20-1753465816667121]; [@bibr7-1753465816667121]\].

The limited resection operative approaches include wedge resection and segmentectomy. Wedge resection is a nonanatomical resection that involves the removal of cancerous lung tissue surrounded by a margin of normal lung parenchyma. Although segmentectomy is more technically challenging, it is an anatomic resection and can usually be used to dissect the lymph nodes more extensively. The wedge resection is generally considered less effective than anatomic segmentectomy for the following two reasons: (a) in wedge resection, the regional lymph nodes of the tumor are usually not removed immediately; (b) compared with segmentectomy, the margin of the staple line in wedge resection is closer to the tumor. However, several recently published articles comparing the main outcomes of patients with stage I NSCLC who were treated with one of these procedures reported conflicting results, which makes it difficult to determine which procedure is the best limited resection approach for patients with stage I NSCLC \[[@bibr12-1753465816667121]; [@bibr10-1753465816667121]; [@bibr4-1753465816667121]; [@bibr19-1753465816667121]\]. The outcomes of wedge resection and segmentectomy for patients with stage I NSCLC may be clarified by two ongoing randomized controlled trials: JCOG0802/WJOG4607L and CALGB 140503 \[[@bibr1-1753465816667121]; [@bibr2-1753465816667121]\]. However, neither of these studies has reported the final results. In this study, we use the meta-analysis method to combine the currently published data and further provide powerful evidence to promote common consensus on the topic.

The aim of this meta-analysis of published studies was to compare the outcomes of overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS) for patients with stage I NSCLC who underwent either wedge resection or segmentectomy. In the subgroup analysis, we compared the OS and CSS results of segmentectomy and wedge resection in patients with stage Ia NSCLC and a tumor size of 2 cm or less. This is an important meta-analysis focused on comparing the outcomes of segmentectomy and wedge resection for patients with NSCLC in stage I, including stage Ia and T1a (tumor size ⩽ 2 cm). Through this pooled analysis, we hope to promote consensus about the surgical options for patients with stage I NSCLC undergoing limited resection.

Methods {#section6-1753465816667121}
=======

Search strategy for published studies {#section7-1753465816667121}
-------------------------------------

According to the recommendations of the Cochrane Collaboration, we established a rigorous study protocol at the beginning of the search. To ensure that the highest quality of literature was included in this meta-analysis, we prespecified the objective, inclusion and exclusion criteria, primary outcome, and methods of synthesis \[[@bibr5-1753465816667121]\].

A systematic and rigorous electronic search was independently performed by two investigators using MEDLINE, EMBASE, and the Cochrane Library database CENTRAL from their earliest publication dates to June 2015. All articles involving patients with stage I NSCLC who underwent segmentectomy or wedge resection were included in the analysis to allow our search strategy to reach the maximum sensitivity, and to ensure that all potentially relevant studies were identified. The search terms were 'lung cancer', 'NSCLC', 'stage I', 'segmentectomy', 'segmental resection', 'sublobar', 'sublobectomy', and 'wedge'. Medical subject headings (MeSH) 'NSCLC' (MeSH), 'sublobar' (MeSH), 'wedge' (MeSH), and 'segmentectomy' (MeSH) were used in combination with the Boolean operators AND or OR. In this study, ethical approval was waived because it was a meta-analysis and did not involve patients.

Selection criteria {#section8-1753465816667121}
------------------

Eligible studies were identified as those articles in which outcomes, including OS, CSS, or DFS, were presented for patients with stage I NSCLC who underwent wedge resection or segmentectomy. Most of the patients included in the analysis were high-risk lobectomy patients. The definition of high risk was not consistent across studies, but most definitions were similar to the definitions used in the published criteria \[[@bibr3-1753465816667121]\]. According to the included studies, high-risk patients were defined as NSCLC patients with a predicted forced expiratory volume in 1 s ⩽ 60%, severe emphysema, poor left ventricular function (defined as an ejection fraction of 40% or less), or severe coronary heart disease. The search results were evaluated according to the prespecified inclusion and exclusion criteria. The following inclusion criteria were established before conducting the search: (a) the surgical procedure could include both wedge resection and segmentectomy; (b) one of the outcomes included OS, CSS, or DFS; (c) articles were original and published andwhose study subjects were limited to patients with clinical stage I NSCLC; (d) the median follow-up time was to exceed 2 years. The exclusion criteria were as follows: (a) letters to the editor, articles published in books, reviews, and papers not published in English; (b) duplicate trials published by centers with accumulating patient numbers or with extended follow-up times; in such cases, only the latest and most informative article was included in the meta-analysis for rigorous qualitative appraisal.

Quality assessment {#section9-1753465816667121}
------------------

We assessed the quality of the included studies based on the Newcastle--Ottawa scale (NOS) for evaluating the quality of case-control and cohort studies. A star system for the NOS (range, 0--9 stars) was developed for the evaluation. The values for the included studies are shown in [Table 1](#table1-1753465816667121){ref-type="table"}.

###### 

Characteristics of included trials.

![](10.1177_1753465816667121-table1)

  Author              Year                         Surgical procedure   Tumor stage   NOS score        
  ------------------- ---------------------------- -------------------- ------------- ---------------- ---
  Okada *et al.*      [@bibr12-1753465816667121]   123                  35            Ia (⩽ 20 mm)     6
  Okada *et al.*      [@bibr12-1753465816667121]   64                   14            Ia (20--30 mm)   
  Okada *et al.*      [@bibr12-1753465816667121]   34                   6             Ib (\> 30 mm)    
  Okada *et al.*      [@bibr11-1753465816667121]   214                  30            Ia               7
  Sienel *et al.*     [@bibr14-1753465816667121]   56                   31            Ia               7
  Sienel *et al.*     [@bibr14-1753465816667121]   35                   25            Ia (⩽ 20 mm)     
  Yamato *et al.*     [@bibr22-1753465816667121]   153                  93            Ia (⩽ 20 mm)     8
  Sugi *et al.*       [@bibr17-1753465816667121]   33                   15            Ia               8
  Nakamura *et al.*   [@bibr10-1753465816667121]   38                   84            I                9
  Hamatake *et al.*   [@bibr4-1753465816667121]    32                   34            Ia (⩽ 10 mm)     8
  Smith *et al.*      [@bibr15-1753465816667121]   378                  1568          I                7
  Tsutani *et al.*    [@bibr19-1753465816667121]   56                   93            Ia               8

NOS, Newcastle--Ottawa scale for quality of case-control and cohort studies.

Statistical analysis {#section10-1753465816667121}
--------------------

The meta-analysis was completed by combining the OS/CSS/DFS data in the published articles. The logarithm of the hazard ratio (HR) and its standard error (SE) were used as the outcome measures for data combination \[[@bibr2-1753465816667121]\]. Using the techniques described by Tierney and colleagues, we obtained or calculated the HR and the associated variance for each selected study \[[@bibr18-1753465816667121]; [@bibr2-1753465816667121]\]. The SE was calculated as (upper 95% confidence interval \[CI\]-lower 95% CI)/3.92 \[[@bibr1-1753465816667121]\]. As the HR of the OS/CSS/DFS data could not be obtained directly from some studies, data were extracted from the Kaplan--Meier survival curves of these studies to calculate the HR and SE of the OS/CSS/DFS data \[[@bibr1-1753465816667121]\]. Kaplan--Meier curves were read using the Engauge Digitizer version 4.1 software, and calculations were performed independently by two researchers. The two researchers discussed any discrepancies to reach consensus. We used the Review Manager version 5.1.2 software to summarize the statistical analysis. Statistical heterogeneity among the included clinical trials was evaluated using Higgins I^2^ statistic, which represents the total variation percentage across studies. If the I^2^ statistic was more than 50%, the random-effects model was used to pool studies; otherwise, the fixed-effect model was used.

Results {#section11-1753465816667121}
=======

Characteristics of included trials {#section12-1753465816667121}
----------------------------------

Nine studies (1181 patients who underwent segmentectomy and 2003 patients who underwent wedge resection) that met the inclusion criteria were identified; all were performed between 2005 and 2015. [Figure 1](#fig1-1753465816667121){ref-type="fig"} shows a flow chart of the literature search for the meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@bibr9-1753465816667121]\]. Our search strategy yielded a total of 339 articles. We reviewed the full text of 22 articles and finalized a list of 9 comparable studies with a total of 3184 patients for inclusion in the analysis. [Table 1](#table1-1753465816667121){ref-type="table"} shows the details of each trial, including baseline characteristics, publication year of the study, surgical procedure, and tumor stage for each trial \[[@bibr12-1753465816667121], [@bibr11-1753465816667121]; [@bibr14-1753465816667121]; [@bibr22-1753465816667121]; [@bibr17-1753465816667121]; [@bibr10-1753465816667121]; [@bibr4-1753465816667121]; [@bibr15-1753465816667121]; [@bibr19-1753465816667121]\].

![The literature search based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. CSS, cancer-specific survival; DFS, disease-free survival; OS, overall survival.](10.1177_1753465816667121-fig1){#fig1-1753465816667121}

Primary outcome measures {#section13-1753465816667121}
------------------------

Pooled estimates were calculated for the primary outcomes of OS, CSS, or DFS following the surgical procedure (segmentectomy or wedge resection). Subgroup analyses were conducted according to the tumor stage and tumor size.

A total of seven studies were included in the analysis of the OS rate. These studies included 904 patients who underwent segmentectomy and 1917 patients who underwent wedge resection. The combined HR of the OS for segmentectomy and wedge resection for patients with stage I NSCLC was 0.80 \[95% CI, 0.68--0.93; *p* = 0.004\] ([Figure 2](#fig2-1753465816667121){ref-type="fig"}). However, in the subgroup analysis of segmentectomy and wedge resection in patients with stage Ia NSCLC with T1a, the combined HR for OS was 0.42 (95% CI, 0.18--0.97; *p* = 0.04), and 0.39 (95% CI, 0.15--1.02; *p* = 0.06), respectively ([Figure 3](#fig3-1753465816667121){ref-type="fig"}). This result indicated that the OS for segmentectomy was superior to that of wedge resection in patients with stage I and stage Ia NSCLC. However, based on our subgroup analysis, the OS for segmentectomy was comparable to that of wedge resection in patients with T1a NSCLC.

![Forest plot of comparison: the overall survival (OS) of segmentectomy versus wedge resection in patients with stage I non-small cell lung cancer. Seven studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig2){#fig2-1753465816667121}

![Forest plot of comparison: segmentectomy overall survival (OS) *versus* wedge resection OS in patients with stage Ia and tumor size ⩽ 2 cm (T1a) non-small cell lung cancer . Seven studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig3){#fig3-1753465816667121}

The CSS data were reported in five studies that included 655 patients who underwent segmentectomy and 1654 patients who underwent wedge resection. As shown in [Figure 4](#fig4-1753465816667121){ref-type="fig"}, the comparative data showed a significant difference because the combined HR for CSS was 0.42 (95% CI, 0.20--0.88; *p* = 0.02). Another subgroup analysis of segmentectomy and wedge resection was also performed according to tumor stage. In this subgroup analysis, the combined HR for CSS was 0.40 (95% CI, 0.18--0.86; *p* = 0.02) for patients with stage Ia NSCLC and 1.87 (95% CI, 0.29--12.06; *p* = 0.51) for patients with T1a NSCLC ([Figure 5](#fig5-1753465816667121){ref-type="fig"}). Based on the above analysis, the CSS of patients with stage I and stage Ia NSCLC treated with segmentectomy was superior to that of patients treated with wedge resection. However, for patients with stage I NSCLC with a tumor size of 2 cm or less, the CSS for segmentectomy was comparable to that of wedge resection.

![Forest plot of comparison: the cancer-specific survival (CSS) of segmentectomy *versus* wedge resection in patients with stage I non-small cell lung cancer. Five studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig4){#fig4-1753465816667121}

![Forest plot of comparison: the cancer-specific survival (CSS) of segmentectomy *versus* wedge resection in patients with stage Ia and tumor size ⩽ 2 cm (T1a) non-small cell lung cancer. Three studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig5){#fig5-1753465816667121}

Only three studies reported the DFS. These studies included 303 patients who underwent segmentectomy and 138 patients who underwent wedge resection. All patients included in the two studies were in stage Ia NSCLC. As shown in [Figure 6](#fig6-1753465816667121){ref-type="fig"}, no statistically significant difference was found between the two surgical procedure groups for DFS, and the combined HR was 0.49 (95% CI, 0.04--6.64; *p* = 0.59).

![Forest plot of comparison: segmentectomy disease-free survival (DFS) *versus* wedge resection DFS in patients with stage Ia non-small cell lung cancer. Three studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig6){#fig6-1753465816667121}

The included studies span 2005--2015, which includes the periods before and after the introduction and routine use of positron emission tomography scanners. We performed a further subgroup analysis to compare the OS rates of the publication year ranges 2005--2010 and 2010--2015. When comparing the OS rates for segmentectomy and wedge resection for patients with stages I and Ia NSCLC by pooling the studies published in 2005--2010, only two studies were included, and the combined HR was 0.41 (95% CI, 0.16--1.05; *p* = 0.06) and 0.96 (95% CI, 0.05--17.96; *p* = 0.98), respectively ([Figures 7](#fig7-1753465816667121){ref-type="fig"} and [8](#fig8-1753465816667121){ref-type="fig"}). However, when comparing the segmentectomy and wedge resection OS rates for patients with stage I NSCLC by pooling the studies published in 2011--2015, four studies were included, and the combined HR was 0.81 (95% CI, 0.70--0.95; *p* = 0.01) ([Figure 9](#fig9-1753465816667121){ref-type="fig"}).

![Forest plot of comparison: segmentectomy overall survival (OS) *versus* wedge resection OS in patients with stage I non-small cell lung cancer in the period 2005--2010. Two studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig7){#fig7-1753465816667121}

![Forest plot of comparison: segmentectomy overall survival (OS) *versus* wedge resection OS in patients with stage Ia non-small cell lung cancer in the period 2005--2010. Two studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig8){#fig8-1753465816667121}

![Forest plot of comparison: segmentectomy overall survival (OS) *versus* wedge resection OS in patients with stage I non-small cell lung cancer in the period 2010--2015. Four studies were included. CI, confidence interval; df, degrees of freedom; SE, standard error.](10.1177_1753465816667121-fig9){#fig9-1753465816667121}

Sensitivity analysis and publication bias {#section14-1753465816667121}
-----------------------------------------

The findings were similar whether fixed- or random-effects models were used. A funnel plot estimating the precision of the trials (plots of the logarithm of the HR for efficacy against sample size) was examined for asymmetry to determine publication bias.

Discussion {#section15-1753465816667121}
==========

Anatomic lobectomy is considered to be the standard surgical procedure for patients with stage I NSCLC. However, sublobar resection is an alternative operation for patients with stage I NSCLC who are considered to be at high risk for complications or mortality with lobectomy \[[@bibr11-1753465816667121]; [@bibr15-1753465816667121]\]. Although wedge resection and segmentectomy are the two sublobar resections that can be used to treat these patients, the type of sublobar resection that produces the better outcomes remains controversial \[[@bibr11-1753465816667121]; [@bibr14-1753465816667121]\]. Therefore, we combined relevant studies and performed a meta-analysis to reach a conclusion on the topic. This analytical approach to studying patients with stage I NSCLC who have undergone segmentectomy or wedge resection has not been performed in the previously published literature.

In this meta-analysis, we found that segmentectomy is associated with significantly better CSS and OS in patients with stage I and stage Ia NSCLC than wedge resection, which suggests the use of segmentectomy decreases stage I NSCLC deaths at a greater rate than wedge resection. However, based on subgroup analyses in patients with T1a NSCLC, we found that the wedge resection OS and CSS rates were equivalent to those of segmentectomy. Furthermore, we noticed that the DFS outcome of wedge resection was comparable to that of segmentectomy in patients with stage Ia NSCLC. For patients with stage I NSCLC, including T1a,bN0M0, T2aN0M0, and T2bN0M0 patients, the above analysis indicates that the relative survival results of segmentectomy and wedge resection in T2aN0M0 NSCLC patients are still unknown. We could not collect the original T2aN0M0 data from all the included studies, and this is a weakness of our study. However, through this meta-analysis, we found a trend and tested a hypothesis that for patients with stage I NSCLC, the larger the tumor size, then the more obvious the advantage of segmentectomy over wedge resection would be. In addition, the results of the subgroup analysis based on the publication year periods 2005--2010 and 2011--2015 did not contradict this conclusion. In this subgroup analysis we also found that during the period 2005--2010 the OS of segmentectomy and wedge resection in patients with stage I NSCLC was comparable ([Figure 7](#fig7-1753465816667121){ref-type="fig"}). However during the period 2010--2015 the OS of segmentectomy was superior to wedge resection in patients with stage I NSCLC ([Figure 9](#fig9-1753465816667121){ref-type="fig"}).

There are several limitations and strengths of this study that should be noted. (a) The level of evidence was relatively low because most of the included articles were retrospective studies. (b) The radiotherapy and chemotherapy data for the cohorts could not be collected and analyzed, which might affect the survival rates of patients with stage I NSCLC in some way. (c) The most important factor affecting the results in each included study was the choice of indications for limited resection. In some included studies, patients who underwent wedge resection were at higher risk of death due to their underlying physiology and comorbidity. In addition, we assumed in this study that anyone who received sublobar resection was at high risk for negative outcomes, but not all included studies provided such detailed information. (d) Details of demographic data (e.g. size, age, histology, and margin status), which may influence the results, were not available for analysis in this study. Despite the existence of the above limitations, the results of this meta-analysis provide important evidence of the relative outcomes of segmentectomy and wedge resection.

The role of segmentectomy and wedge resection may be clarified by two ongoing randomized controlled clinical trials: a phase III randomized controlled trial (WJOG4607L/JCOG0802) launched by the West Japan Oncology Group and Japan Clinical Oncology Group in 2009 and a phase III randomized trial (CALGB 140503) launched by the National Cancer Institute in 2008. In CALGB 140503, more than 1200 patients in a multi-center design will be recruited for a randomized study comparing lobectomy and sublobar resection (segmentectomy and wedge resection) for stage Ia NSCLC with peripheral tumors that are no larger than 2 cm in diameter. Although the main purpose of this research is to compare lobectomy and sublobar resection, it is believe that a subgroup analysis comparing segmentectomy and wedge resection will also be performed. The follow-up period is 3 years, and the accrual period is 5 years. There is no doubt that the final outcomes of these two clinical trials will have an important impact on the surgical management (segmentectomy or wedge resection) of patients with stage I NSCLC who are undergoing limited resection.

In conclusion, this meta-analysis disclosed two important findings: (a) OS and CSS rates for patients with stage I NSCLC after segmentectomy are superior to those obtained after wedge resection; (b) wedge resection and segmentectomy produce similar CSS and OS rates for patients with NSCLC in stage Ia with a tumor size of 2 cm or less. Considering the limitations and heterogeneity of the included studies, the results and conclusions of the meta-analysis should be further confirmed by rigorous randomized clinical trials.
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